Ex-Novartis Exec Unveils Neurodegeneration Gene Therapy Start-Up AviadoBio
Lisa Deschamps Commercialized Novartis’s Zolgensma
AviadoBio believes it can overcome barriers to making gene therapy work in neurodegenerative diseases, and its new CEO knows what it takes to make a commercial success in the field.
You may also be interested in...
Micro-Dosing Gene Therapy: A Recipe For Success?
Utilizing the genetic overlap between frontotemporal dementia and amyotrophic lateral sclerosis, AviadoBio is seeking to develop gene therapies which can stop both these devastating diseases in their tracks using novel delivery techniques.
Pfizer Gets AAV Capsid Rights From Voyager For Gene Therapy R&D
Deal Snapshot: Pfizer has 12 months to evaluate a pair of AAV capsids from Voyager’s TRACER platform for use as delivery mechanisms in gene therapy candidates for neurologic and CV indications.
Roche Shelves Phase III Huntington's Candidate Tominersen
Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.